Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX) and the PAM50 Breast Cancer Intrinsic Classifier in Early-Stage Estrogen Receptor–Positive Breast Cancer
The Oncologist, 04/25/2012Kelly CM et al.
The findings suggest that there is good agreement between the two assays for high and low prognostic risk assignment but PAM50 assigns more patients to the low risk category. About half of the intermediate Recurrence Score (RS) group was reclassified as luminal A by PAM50.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.